Sangamo Therapeutics (SGMOQ) Operating Leases (2019 - 2025)

Sangamo Therapeutics' Operating Leases history runs 7 years deep, the most recent figure standing at $25.1 million for Q4 2025.

• On a quarterly basis, Operating Leases fell 4.42% year-over-year to $25.1 million in Q4 2025; TTM through Dec 2025 was $25.1 million, a 4.42% decrease from a year earlier, with the FY2025 full-year figure at $25.1 million, down 4.42% from the prior year.
• Operating Leases retreated to $25.1 million in Q4 2025 per SGMOQ's latest filing, from $25.4 million in the prior quarter.
• Across five years, Operating Leases topped out at $44.1 million in Q4 2021 and bottomed at $23.5 million in Q2 2025.
• The 5-year median for Operating Leases is $35.7 million (2023), against an average of $34.3 million.
• Across the five-year window, Operating Leases advanced 14.74% in 2021 and decreased 21.67% in 2024, its largest moves.
• Year by year, Operating Leases stood at $44.1 million in 2021, then fell by 11.51% to $39.0 million in 2022, then decreased by 14.03% to $33.5 million in 2023, then dropped by 21.67% to $26.3 million in 2024, then slipped by 4.42% to $25.1 million in 2025.
• Per Business Quant, the three latest SGMOQ Operating Leases figures stand at $25.1 million (Q4 2025), $25.4 million (Q3 2025), and $23.5 million (Q2 2025).